Xenetic Biosciences (NASDAQ:XBIO) announced an abstract acceptance for presentation at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago.
The poster, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," will be presented June 1, 2026, 9:00 AM–12:00 PM CDT (Poster Board 410) by Alexey V. Stepanov, PhD, in the Hematologic Malignancies - Plasma Cell Dyscrasia session.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – XBIO
+1.92%
1 alert
+1.92%News Effect
-2.4%Trough Tracked
+$145KValuation Impact
$7.68MMarket Cap
0.3xRel. Volume
On the day this news was published, XBIO gained 1.92%, reflecting a mild positive market reaction.
Argus tracked a trough of -2.4% from its starting point during tracking.
This price movement added approximately $145K to the company's valuation, bringing the market cap to $7.68M at that time.
VolumeVolume 9,036 is 0.53x the 20-day average of 16,899, indicating below-normal activity pre-announcement.low
TechnicalXBIO at $3.13 trades above its 200-day MA of $2.98 but remains 77.53% below the 52-week high of $13.93.
Peers on Argus
XBIO fell 7.94% while momentum-screened peers GRI and SLXN gained 4.76% and 6.00...
2 Up
XBIO fell 7.94% while momentum-screened peers GRI and SLXN gained 4.76% and 6.00%. In the broader peer list, names like OGEN (-7.34%) and APVO (-0.58%) were weaker, while PALI jumped 12.45%, pointing to mixed, stock-specific moves rather than a unified sector reaction.
Recent positive operational updates have produced mixed reactions, with some earnings events aligning positively and others seeing mild selloffs despite constructive progress.
Recent Company History
This announcement builds on Xenetic’s DNase I immuno‑oncology work highlighted in prior updates. In Q3 2025, the company reported royalty-driven revenue of about $1.0M and net loss of roughly $0.5M, followed by a full-year 2025 net loss of $2.7M and royalty revenue of $3.0M. A 4‑month extension of the Scripps collaboration advanced systemic DNase I/CAR‑T programs toward a planned Phase 1 trial. The ASCO abstract acceptance reflects continued preclinical momentum within this same platform.
Market Pulse Summary
This announcement underscores scientific validation for Xenetic’s DNase I approach, with acceptance ...
Analysis
This announcement underscores scientific validation for Xenetic’s DNase I approach, with acceptance of preclinical CAR‑T data for presentation at the 2026 ASCO meeting. It follows prior updates on royalty revenue of about $3.0M, a full-year net loss of $2.7M, and collaboration progress toward a Phase 1 trial. Investors may watch for clinical trial initiation, additional data disclosures, and any strategic review outcomes highlighted in recent SEC filings.
Key Terms
immuno-oncology, american society of clinical oncology, cfdna, nets, +4 more
8 terms
immuno-oncologymedical
"a biopharmaceutical company focused on advancing innovative immuno-oncology technologies"
Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.
american society of clinical oncologymedical
"accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting"
A professional organization of cancer doctors, researchers and care teams that publishes clinical guidelines and hosts major conferences where new treatment trial results are presented. Investors watch its announcements because its guidelines and conference findings often shape which drugs and technologies are accepted by doctors and hospitals—similar to a respected referee whose rulings can change the commercial prospects and perceived value of healthcare companies.
cfdnamedical
"Targeting cfDNA and NETs with DNase I to augment CAR T cell function"
Cell-free DNA (cfDNA) is short fragments of genetic material that float freely in the bloodstream after cells die and release their contents. Investors care because cfDNA can be sampled with a simple blood draw to reveal signs of pregnancy complications, organ damage, or cancer without invasive procedures, making it the basis for high-growth diagnostic tests, monitoring tools and companion products that can change how diseases are detected and treated.
netsmedical
"Targeting cfDNA and NETs with DNase I to augment CAR T cell function"
Nets describes the final amount a company or transaction produces after all additions and subtractions — for example, revenue minus costs, taxes, fees, or other adjustments. For investors, the “net” figure shows the real, take-home result that affects profit, cash flow and valuation, much like the difference between gross pay and your take-home pay after payroll deductions.
dnase imedical
"with DNase I to augment CAR T cell function and antitumor efficacy"
DNase I is an enzyme that cuts DNA strands into smaller pieces, like molecular scissors that break long threads into shorter fragments. For investors, DNase I matters because it is used in medical treatments, laboratory tests and manufacturing processes; changes in clinical trial results, regulatory approval, patent control, or production capacity can affect companies’ revenues and costs in biotech, diagnostics and contract manufacturing.
car t cellmedical
"DNase I to augment CAR T cell function and antitumor efficacy"
CAR T cell therapy uses a patient’s own immune cells that have been reprogrammed in a lab to recognize and attack cancer cells. Think of it as fitting a person’s immune “soldiers” with a custom GPS that guides them to a specific enemy marker on tumor cells. For investors, CAR T matters because it can deliver dramatic clinical benefits but also involves complex manufacturing, high costs, regulatory hurdles, and significant potential upside or downside for drug developers and healthcare payers.
Hematologic malignancies are types of cancers that start in the blood or the organs responsible for blood production, like the bone marrow and lymph nodes. They matter because they can disrupt normal blood functions, leading to issues like weakness, infections, or abnormal growths, and often require specialized treatments.
A plasma cell dyscrasia is a medical condition in which the antibody-making white blood cells grow or behave abnormally, often producing too much of a single, abnormal protein. For investors, these disorders matter because they range from mild, watch-and-wait conditions to serious cancers that drive demand for diagnostics, therapies and ongoing care; changes in prevalence, treatment approvals, or clinical-trial results can directly affect the value and prospects of healthcare companies.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL.
The accepted abstract, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," highlights preclinical research supporting Xenetic's DNase-based therapeutic approach designed to enhance CAR T-cell activity and improve antitumor responses.
Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy
Poster Board: 410
Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT
Presenter: Alexey V. Stepanov, PhD
The poster will be available to conference attendees during the scheduled session. For more information, please visit asco.org.
About Xenetic Biosciences Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
What will Xenetic Biosciences (XBIO) present at the 2026 ASCO Annual Meeting?
Xenetic will present preclinical research on a DNase I approach to boost CAR T-cell activity. According to Xenetic, the poster titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy" is accepted for a June 1 poster session.
When and where is Xenetic's (XBIO) poster presentation scheduled at ASCO 2026?
The Xenetic poster is scheduled for June 1, 2026, 9:00 AM–12:00 PM CDT in Chicago. According to Xenetic, the poster will be displayed at Poster Board 410 during the Hematologic Malignancies - Plasma Cell Dyscrasia session.
Who will present Xenetic's (XBIO) ASCO 2026 poster and what is their role?
Alexey V. Stepanov, PhD, will present Xenetic's poster at ASCO 2026. According to Xenetic, Dr. Stepanov is the listed presenter for the June 1 poster on DNase I effects on CAR T-cell function and antitumor efficacy.
What is the focus of Xenetic's (XBIO) ASCO abstract on DNase I and CAR T cells?
The abstract focuses on targeting cfDNA and NETs with DNase I to enhance CAR T-cell function and antitumor responses. According to Xenetic, the work reports preclinical evidence supporting a DNase-based therapeutic approach to augment CAR T activity.
How can attendees find Xenetic's (XBIO) poster at the ASCO 2026 meeting?
Attendees can view Xenetic's poster at Poster Board 410 during the June 1, 9:00 AM–12:00 PM CDT session. According to Xenetic, the poster is part of the Hematologic Malignancies - Plasma Cell Dyscrasia poster session.
Will Xenetic's (XBIO) ASCO poster be available after the conference for review?
The poster will be available to conference attendees during the scheduled session; broader availability is not specified. According to Xenetic, interested parties should consult ASCO resources for post-conference access and additional details.
